RXRX Recursion Pharmaceuticals
AI drug discovery with NVIDIA-backed compute
Fundamentals from public market data, refreshed daily (2026-11-12 22:21 UTC). Figures in reporting currency.
RXRX · price with what management and the data said
Timeline: management commentary, data & earnings
8 events-
8
2026-11-02EarningsBeat / raise
Reported EPS -0.22 vs -0.23 expected (+3.9% surprise).
-
7
2026-08-05EarningsMiss / cut
Reported EPS -0.25 vs -0.23 expected (-6.8% surprise).
-
6
2026-05-06EarningsBeat / raise
Reported EPS -0.22 vs -0.26 expected (+14.4% surprise).
-
5
2026-02-25EarningsBeat / raise
Reported EPS -0.21 vs -0.32 expected (+33.3% surprise).
-
4
2025-11-05EarningsBeat / raise
Reported EPS -0.36 vs -0.38 expected (+5.7% surprise).
-
3
2025-08-05EarningsMiss / cut
Reported EPS -0.41 vs -0.35 expected (-16.0% surprise).
-
2
2025-05-05EarningsBeat / raise
Reported EPS -0.5 vs -0.52 expected (+3.1% surprise).
-
1
2025-02-28EarningsMiss / cut
Reported EPS -0.53 vs -0.42 expected (-27.2% surprise).
Latest headlines
Auto-updated daily- Recursion to Participate in Upcoming Investor Conferences2026-11-11
- Recursion Pharmaceuticals Inc (RXRX) Q3 2026 Earnings Call Highlights: Durable FAP Data, Early ...2026-11-11
- AI in Predictive Toxicology - Global Strategic Business Report 2026: Capture a $3.2 Billion Market by 2032 as BenevolentAI, Insilico Medicine, Recursion Pharmaceuticals and Revvity Disrupt Testing2026-11-09
- Is Recursion Pharmaceuticals (RXRX) A Bargain After Q3 Earnings And Clinical Updates?2026-11-05
- REC 4881 Trial Results Could Change The Case For Recursion Pharmaceuticals Stock2026-11-05
- Recursion Pharmaceuticals (RXRX) Puts Fred Hassan In The Chair After Phase 2 Win2026-11-04
- RXRX Q3 Earnings Call Highlights Clinical Progress and Cash Runway2026-11-04
Earnings history
EPS vs expectations| Date | Expected EPS | Reported EPS | Surprise |
|---|---|---|---|
| 2026-11-02 | -0.23 | -0.22 | +3.9% |
| 2026-08-05 | -0.23 | -0.25 | −6.8% |
| 2026-05-06 | -0.26 | -0.22 | +14.4% |
| 2026-02-25 | -0.32 | -0.21 | +33.3% |
| 2025-11-05 | -0.38 | -0.36 | +5.7% |
| 2025-08-05 | -0.35 | -0.41 | −16.0% |
| 2025-05-05 | -0.52 | -0.5 | +3.1% |
| 2025-02-28 | -0.42 | -0.53 | −27.2% |
| 2024-11-06 | -0.33 | -0.34 | −2.1% |
| 2024-08-08 | -0.38 | -0.4 | −4.2% |
| 2024-05-09 | -0.43 | -0.39 | +8.6% |
| 2024-02-27 | -0.45 | -0.42 | +6.4% |
| 2023-11-09 | -0.39 | -0.43 | −11.6% |
| 2023-08-08 | -0.37 | -0.38 | −1.3% |
| 2023-05-08 | -0.35 | -0.34 | +3.0% |
| 2023-02-27 | -0.24 | -0.3 | −26.8% |
| 2022-11-08 | -0.38 | -0.35 | +7.6% |
| 2022-08-09 | -0.37 | -0.38 | −1.8% |
| 2022-05-10 | 0.51 | -0.33 | −164.7% |
| 2022-03-23 | -0.31 | -0.38 | −23.6% |
| 2021-11-10 | -0.28 | -0.28 | +0.1% |
| 2021-08-13 | -0.24 | -0.31 | −28.6% |
| 2021-05-12 | -0.23 | -0.23 | +1.0% |
About Recursion Pharmaceuticals
Website ↗Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes R…
Models now design molecules and antibodies, but clinical trials are still the gate. Value accrues to platforms with wet-lab data and pharma partnerships.
What would prove us wrong. Weakens if AI-designed candidates fail in the clinic at rates no better than traditional discovery.
Who else supplies this
| Stock | Role | Last | 1D | 1M | YTD | Trend |
|---|---|---|---|---|---|---|
| SDGR Schrödinger | Physics-plus-AI molecular design software | $30.85 | −2.13% | +23.1% | +72.5% | |
| ABSI Absci | Generative-AI antibody design | $9.13 | −9.73% | +4.5% | +161.8% | |
| ABCL AbCellera Biologics | AI-driven antibody discovery | $11.62 | −2.76% | −6.1% | +239.8% | |
| TEM Tempus AI | Clinical and genomic data for AI diagnostics | $75.89 | −4.46% | +11.1% | +28.5% |
Not investment advice. Prices delayed and in local currency. Quotes in "double quotes" are verbatim as reported by the linked source; other commentary is our paraphrase. Earnings dates are estimates.